Follicum AB have announced that the firstpatient has been treated in the Phase IIa clinical trial in Germany with its lead candidate FOL-005 on 60 patients with hair loss. The study is conducted at Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin and bioskin, Hamburg, Germany. The global market for pharmaceutical hair lossproducts for both men and women is estimated to be worth $3 billion. The available drug products have unwanted side-effects that limit their use.
08 March, 2018